Our equity story

UCB’s Decade+ of Growth: Elevating lives of people through our medicines

 

 

Our key medicines

We bring solutions to people living with neurological or immunological diseases.

 

Growth drivers

 

BIMZELX® (bimekizumab).

Reaching more than >135 000 patients globally in H1 2026

Indications: Psoriasis (PSO); Psoriatic Arthritis (PsA); Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA), hidradenitis suppurativa (HS)

Loss of Exclusivity (indicative): 2035 in U.S., without patent term extension; 2036 in Europe, 2037 in Japan

Sales: € 1.52 billion in HY 2026

Peak sales guidance: > € 7 billion

 

EVENITY® (romosozumab)

Reached more than 1 500 000 patients globally since launch

Indication: Osteoporosis

Loss of Exclusivity (indicative): 2031 in Europe and Japan, 2033 in U.S.

Sales: € 88 million in HY 2026 in Europe. Net sales outside Europe reported by Amgen and Astellas

 

FINTEPLA® (fenfluramine)

Reaching more than 16 000 patients globally

Indications: Dravet Syndrome, Lennox-Gastaut Syndrome.

Loss of Exclusivity (indicative). 2032 in Europe and Japan, 2033 in U.S.

Sales: € 239 million in HY 2026.

Peak sales guidance: € 800 million by 2027.

 

RYSTIGGO® (rozanolixizumab)

Launched in the U.S. in July 2023, approved and launched in Europe and Japan

Indication: generalized Myasthenia Gravis.

Loss of Exclusivity (indicative): 2037 in Japan. 2034 in Europe and 2035 in U.S., all without patent term extension.

Sales: € 192 million in HY 2026.

 

ZILBRYSQ® (zilucoplan)

Global launches started April 2024

Indication: generalized Myasthenia Gravis.

Loss of Exclusivity (indicative): 2035 in Europe, U.S. without patent term extension. Japan 2040.

Sales: € 139 million in HY 2026

 

Solid foundation

 

BRIVIACT® (brivaracetam)

Indication: Epilepsy partial-onset seizure, also known as focal seizure

Loss of Exclusivity (indicative): August 2026 in Europe & U.S. and 2034 in Japan

Sales: €327 million in HY 2026

Peak sales guidance: ≥ € 600 million by 2026, reached 2 years ahead of time

 

CIMZIA® (certolizumab pegol)

Indications: Ankylosing spondylitis (AS); non-radiographic Axial Spondyloarthritis (nr-axSpA); Crohn's disease (CD); Psoriasis (PSO); Psoriatic arthritis (PsA); Rheumatoid arthritis (RA)

Loss of Exclusivity (indicative): 2026 in Japan.

Sales: € 954 million in HY 2026

 

KEPPRA® (levetiracetam)

Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizures; Epilepsy myoclonic seizures

Sales: € 216 million in HY 2026

 

NAYZILAM® (midazolam nasal spray)

Indication: Epilepsy seizure clusters

Loss of Exclusivity (indicative): 2028 in U.S.

Sales: € 81 million in HY 2026

 

VIMPAT® (lacosamide)

Indications: Epilepsy partial-onset seizures, also known as focal seizures; Epilepsy primary generalized tonic-clonic seizures

Loss of Exclusivity: 2022 in Europe & U.S. 2024 in Japan

Sales: € 105 million in HY 2026

 

Our clinical development partnerships

Amgen
Biogen
Cancer Research UK

 

Our clinical development pipeline

UCB remains committed to advancing innovation and delivering meaningful solutions for people living with severe immunological and neurological diseases. This commitment is reflected in its robust clinical development pipeline, further strengthened by the recent acquisitions of Candid Therapeutics and Neurona Therapeutics, which add next-generation therapeutic modalities to the portfolio. An overview of key clinical development milestones, including regulatory submissions, expected data readouts and pipeline advancements since January 1, 2026, is provided below. Updates and changes to UCB’s clinical development pipeline are outlined below.

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Hidradenitis Suppurativa (>9y / 12y-18y)

    PHASE: 3

    INFO: Topline results in H1 2027

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Palmoplantar Pustulosis (PPP)

    PHASE: 3

    INFO: Topline results in 2028

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Psoriasis (6y-18y)

    PHASE: 3

    INFO: Topline results in H2 2027

  • bimekizumab (IL-17 A/F)

    Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Juvenile Idiopathic Arthritis (2y-18y)

    PHASE: 3

    INFO: Topline results in 2028

  • rozanolixizumab (FcRn inhibitor)

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Myelin oligodendrocyte glycoprotein (MOG) antibody disease

    PHASE: 3

    INFO: Topline results in H2 2027 (event driven)

  • rozanolixizumab (FcRn inhibitor)

    Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Ocular myasthenia gravis

    PHASE: 3

    INFO: Phase 3 initiated - Topline results in 2029

  • fenfluramine (5-HT agonist)

    Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: CDKL5 deficiency disorder

    PHASE: 3

    INFO: Positive Phase 4 - Filed

  • fenfluramine (5-HT agonist)

    Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine may reduce seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: RETT-Syndrome

    PHASE: 3

    INFO: Phase 3 initiated - Topline results in 2029

  • dapirolizumab pegol (anti-CD40L antibody)

    Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L). Through interactions with its receptor, CD40, CD40L plays an important role in regulating interactions between T cells and other immune cells and thus affects several important functional events thought to be involved in autoimmune disease.

    Dapirolizumab pegol is being co-developed with Biogen.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Systemic lupus erythematosus

    PHASE: 3

    INFO: Topline results of 2nd phase 3 in 2028

  • STACCATO® alprazolam (benzodiazepine)

    STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine, that has the potential to be the first rescue treatment to be administered by a patient or caregiver in an out-patient setting to rapidly terminate (within 90 seconds) an ongoing seizure.

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: Stereotypical prolonged seizures

    PHASE: 3

    INFO: Topline results in Q4 2026 / H1 2027 (event driven)

  • rezanecel (GABA interneuron cell therapy)

    Rezanecel is an investigational allogenic regenerative GABA interneuron cell therapy, administered in a one-time, minimally invasive delivery procedure designed to integrate into dysregulated neural circuits and restore inhibitory tone.

    MODALITY: Cell therapy

    THERAPEUTIC AREA: Neurology

    INDICATION: Mesial Temporal Lobe Epilepsy

    PHASE: 3

    INFO: Phase 3 to start in H1 2027

  • bepranemab (anti-tau antibody)

    Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody with specificity for human tau protein.

    MODALITY: Monoclonal antibody

    THERAPEUTIC AREA: Neurology

    INDICATION: Alzheimer's disease

    PHASE: 2

    INFO: Signal-confirming Phase 2 to start in H1 2027

  • glovadalen (D1 receptor positive allosteric modulators)

    Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator. This orally available, brain-penetrant, small molecule is designed to enhance the potency of dopamine ‘when and where needed’ to activate the dopamine D1 receptor and thereby improve symptom control. It is being studied for the treatment of Parkinson's disease.

    MODALITY: Small molecule

    THERAPEUTIC AREA: Neurology

    INDICATION: Parkinson's disease

    PHASE: 2

    INFO: Positive Phase 2a. Next steps under evaluation

  • galvokimig (IL-13 & IL-17 A/F)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Atopic dermatitis

    PHASE: 2

    INFO:Phase 2b - Topline results (52-week) in 2028

  • galvokimig (IL-13 & IL-17 A/F)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Non Cystic Fibrosis Bronchiectasis (NCFB)

    PHASE: 2

    INFO:Phase 2 initiated in Q3 2026 - Topline results in 2029

  • galvokimig (IL-13 & IL-17 A/F)

    Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F, with albumin binding to modulate the serum half-life. IL-13, IL-17A and IL-17F are key mediators of inflammation, belonging to distinct and non-redundant inflammatory pathways. It is being studied for the treatment of moderate-to-severe atopic dermatitis, a type of eczema associated with inflammation of the skin, and which causes the skin to become itchy, red, dry and cracked.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Chronic Obstructive Pulmonary Disease (COPD)

    PHASE: 2

    INFO:Phase 2 initiated in Q3 2026 - Topline results in 2029

  • cizutamig (BCMA x CD3 T-cell engager)

    Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing plasma cells and B-cells.

    MODALITY: Multi-specific antibody

    THERAPEUTIC AREA: Immunology

    INDICATION: Myasthenia gravis & Systemic autoimmune rheumatic disease associated interstitial lung disease

    PHASE: 3

    INFO: Phase 2 planned to start end 2026